

Utilizing our strengths to create the new drugs patients need

The Corporate Mission and our three strengths (management resources)

Business activities and strategy

Corporate Mission

To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide

Our Three Strengths



Research & Development

We possess a rich pipeline, drug discovery capability, leading-edge technology and know-how, broad network related to science, and dedicate efforts mainly in the three research focus areas*.

* Three research focus areas: Psychiatry & Neurology, Oncology, Regenerative Medicine/Cell Therapy

→ See page 42

Human Resources

We have a framework that utilizes the capabilities of individual employees, sincere and excellent human resources, and a corporate culture that promotes a spirit of perseverance and precision.

→ See page 60

Global Platform

We have a strong sales network in Japan, North America, and China which forms a base that supports global expansion, and we engage in sales and marketing activities tailored for each region.

→ See page 52

Material issues linked to value creation

- Development of Innovative Products and Healthcare Solutions

Psychiatry & Neurology Area	Oncology Area	Regenerative Medicine / Cell Therapy Field
Infectious Diseases Area	Other Areas	Frontier Business

- Contributing to the Development of Science
- Work Style Innovation
- Training and Development of Employees
- Diversity & Inclusion
- Contribution to Global Health
- Initiatives to Improve Access to Medicines and Others

→ See page 35-36

Business activities

Material issues that forms the foundation for business continuity

- Respecting Human Rights
- Corporate Governance
- Risk Management
- Compliance
- Fair and Transparent Corporate Activities
- Corporate Regulatory Compliance, Quality Assurance and Stable Supply
- CSR Procurement
- Health, Safety, and Welfare of Employees
- Environmental Initiatives

→ See page 37-38

Strategic investment aimed at sustained growth
(includes research and development investment)

Value provided to society

Mid-term Business Plan 2022

Basic Policy I

Establishment of growth engine

1. Enhance innovation base with new approaches to drug discovery
2. Deliver the highest performance of clinical development
3. Pipeline expansion through strategic investment
4. Regional strategy centering in Japan, North America and China
5. Launch frontier business

→ See page 42

Basic Policy II

Building of flexible and efficient organization

- Flexible and efficient organization and operations
- Corporate culture and talent to drive innovation
- Digital transformation

→ See page 57

Patients and their families

Contributing to improving quality of life (QOL)

Shareholders

Stable dividends, increases in dividends linked to improvements in performance

Employees

Personal development, acquiring fulfillment and a sense of happiness through work

Also contributing to achieving the Sustainable Development Goals (SDGs)



Position we aspire to establish in 2033

Global Specialized Player

In addition to becoming a global leader in its three research focus areas of Psychiatry & Neurology, Oncology, and Regenerative Medicine / Cell Therapy, Sumitomo Pharma will work to develop pharmaceuticals, as well as Frontier business where we expect synergies with the pharmaceutical business, aspiring to establish a position as a “Global Specialized Player” in 2033.